Amarin Corp Plc (AMRN)

[Ajax133]

Bottom Line:Even though your attitude is confrontational, I shall try to give you an historical over view. When Omacor was launched, there were many Omega III products on the market. Build a better mouse trap and they shall come. When GSK took over Reliant, they changed the name to Lovaza. It has been doing $1.3B year over year.
with multiple Omega III's supplements on the market. When Zocor was launched, it basically overwhelmed Mevacor. Lipitor did the same to Zocor, as did Crestor to Lipitor. Physicians and patients want the most efficacious product available. The P values for Vascepa for the same indication of elevated Trg's over 500 were off the charts compared to Lovaza. Not sure they teach P values in Dental School, but I'm sure you catch my drift.